NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
March 6, 2007 • Volume 4 / Number 10 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
Study Estimates Overall HPV Prevalence in U.S. Women

Director's Update
Proposed Tobacco Legislation Underscores Need for Research

Special Report
Study Finds Lung Cancer Screening May Not Reduce Deaths

Cancer Research Highlights
Children Often Develop Fragile Bones from Cancer and its Treatment

Strenuous Long-Term Physical Activity Lowers Risk of Breast Cancer

Radiation and Chemo Before Esophageal Cancer Surgery Improves Survival

Spotlight
Aromatase Inhibitors Come of Age

Featured Clinical Trial
Measuring Biological Response to Curcumin

Notes
NCI Launches Redesigned Clinical Trials Pages

New Communications Guide for Breast Cancer Screening Available

Women's Health Week Web Site Launched

Special Issue on Cancer Prevention

NCI 70th Anniversary: If Memory Serves...

Funding Opportunities

CCR Grand Rounds

Bulletin Archive

About the Bulletin

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Featured Article

Study Estimates Overall HPV Prevalence in U.S. Women

Data from the National Health and Nutrition Examination Survey (NHANES) published in the February 28 Journal of the American Medical Association (JAMA) have provided the first national estimate of the prevalence of human papillomavirus (HPV) infection among women in the United States aged 14 to 59. Investigators found that a total of 26.8 percent of women overall tested positive for one or more strains of HPV.

Overall prevalence included both low-risk and high-risk HPV types. Low-risk types of HPV can cause genital warts or other nonmalignant conditions. High-risk types of HPV can cause cervical cancer, and up to 70 percent of cervical cancers worldwide are caused by two high-risk strains alone - HPV types 16 and 18.

HPV Vaccines for Cervical Cancer "We think it's important to let women know how common [HPV] is," says Dr. Eileen Dunne from the Centers for Disease Control and Prevention, lead author of the study.

All women aged 14 to 59 selected to participate in the 2003-2004 NHANES, designed to collect health and nutrition measurements from a representative sample of the U.S. population, were eligible to participate in the HPV study. Most eligible women submitted self-collected cervicovaginal swab samples, 1,921 of which could be used for DNA extraction and HPV detection and typing.

Overall, 26.8 percent of women tested positive for one or more strains of HPV. Prevalence of HPV was highest in women ages 20-24. Among all participating women, the prevalence of high-risk types of HPV was 15.2 percent. The prevalence of HPV types 6, 11, 16, and 18 - the types targeted by the HPV vaccine Gardasil - was 3.4 percent overall, translating to an estimated 3.1 million exposed women in the studied age groups.

An important limitation of this study, explains Dr. Philip Castle, an investigator in NCI's Division of Cancer Epidemiology and Genetics, is that "this prevalence study is only a snapshot of HPV in the country, but doesn't tell us anything about total lifetime exposure to HPV or the risk of precancer and cancer. Risk is not testing positive at one time point - it's the persistence of carcinogenic types of HPV."

Persistence of HPV infection - how long the virus remains active in a woman's body - is key to whether exposure to a high-risk type of HPV leads to cervical cancer. "If an infection from specific oncogenic HPV types does not clear within a period of time (about 6 months), it puts that woman at greater risk for cervical precursor lesions," explains Dr. Dunne.

"There's a lot of misunderstanding about HPV's complex natural history," Dr. Dunne continues. "It's not that if you get the infection, you get the disease. It's a common infection, and a lot of them clear [on their own]. The important thing is that women have routine cervical cancer screening with Pap tests, and appropriate groups of women receive the preventative vaccine that's now available."

The baseline data provided by this study may help researchers determine the public-health impact of HPV vaccination, explain the authors. However, "This is one piece of the big puzzle," says Dr. Dunne. "Looking at diseases such as genital warts, cervical cancer precursors, and cervical cancer will also be necessary to monitor vaccine impact."

"What we need…is a surveillance program that's linked to HPV vaccination uptake over a long period of time, so we can see the impact, and also any potential adverse effects, of an HPV vaccine," agrees Dr. Castle. "By monitoring benefits and risks of HPV vaccination, we can optimize the use of HPV vaccines to achieve the greatest good for women."

By Sharon Reynolds

Headline Readers Beware

While the February 28 JAMA study about HPV prevalence in the United States has generated a great deal of publicity, some of the media coverage is confusing and potentially misleading. Take, for example, the following headlines which appeared in three major newspapers and a cable TV network Web site last week:

"Study: 1 in 4 U.S. Women Infected with Cervical Cancer Virus"

"Millions of Women Carry
HPV Strains that Vaccine Can Block"

"Millions In U.S. Infected
With HPV; Study Finds Virus Strikes a Third of
Women by Age 24"

"Study: Virus Hits 1 in 4 Women"

"While it's true that, based on projections from the survey, millions of women were infected with HPV at the time the survey was conducted, it is not accurate to say that these women are at high risk for developing cervical cancer," said Dr. Philip Castle. "Only some HPV types cause cervical cancer and only if they persist for many years. The vast majority of HPV infections, even by those types which cause cervical cancer, go away within a year or two without treatment.

"It's important for people to understand that two strains of HPV - 16 and 18 - have been found to cause 70 percent of cervical cancers if they persist and are left untreated," continued Dr. Castle. "But even if HPV16 and 18 infections persist, they do not always cause cancer. This is why it's important for the public to clearly understand the role of all types of HPV in causing cervical cancer and other diseases, especially when considering who to vaccinate and at what age."

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov